Revuforj (revumenib) is a novel menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia harboring KMT2A gene translocation. Understanding its side effects and medication precautions is crucial for ensuring effective treatment.

Revuforj (Revumenib): Side Effects and Precautions

Common Side Effects of Revuforj (Revumenib)

Hematological system:

Bleeding (53%).

Febrile neutropenia (35%).

Gastrointestinal system:

Nausea (51%).

Diarrhea (30%).

Constipation (23%).

Metabolic abnormalities:

Elevated blood phosphorus (50%).

Elevated triglycerides (25%).

Infections:

Bacterial infections (31%).

Viral infections (23%).

Others:

Musculoskeletal pain (42%).

Fatigue (22%).

Peripheral edema (23%).

Serious Side Effects of Revuforj (Revumenib) Requiring Vigilance

Differentiation Syndrome (DS)

Incidence rate: 29%, of which 13% are grade 3-4.

Manifestations: Fever, dyspnea, hypotension, rapid weight gain, etc.

Management: Immediate administration of corticosteroids and temporary discontinuation of Revuforj are required.

QTc Interval Prolongation

Incidence rate: 29%, of which 12% are grade 3.

Risk: May induce life-threatening arrhythmias.

Monitoring: Regular electrocardiogram (ECG) and electrolyte monitoring are necessary.

Embryo-Fetal Toxicity

Animal studies: Demonstrated teratogenic risks.

Contraception: Patients of childbearing potential must use effective contraceptive measures.

Severe Infections

Types: Including sepsis (9%) and pneumonia (7%).

Surveillance: Close monitoring for signs of infection is required.

Precautions for Revuforj (Revumenib) Administration

Dose Adjustment

Baseline dose: 270 mg twice daily for adults weighing ≥ 40 kg.

Concomitant use with strong CYP3A4 inhibitors: Dose reduction to 160 mg is required.

Pediatric patients: Dose calculation based on body surface area (BSA).

Monitoring Requirements

Confirmation of KMT2A translocation is mandatory before treatment initiation.

Weekly ECG monitoring for the first 4 weeks of treatment.

Regular tests: Complete blood count, electrolyte levels, and liver function.

Contraindications and Cautions

Concomitant use with strong CYP3A4 inducers is contraindicated.

Caution is advised when used with other drugs that prolong the QT interval.

Special Populations

Pregnancy: Contraindicated.

Lactation: Breastfeeding is prohibited within 1 week after discontinuing the medication.

Pediatric patients: Monitoring of bone development is required.

Administration Method

The tablet can be taken whole or crushed and dissolved in water for administration.

Low-fat diet does not affect the absorption of Revuforj.